loading...| Preferred Name |
daclizumab |
|
| Synonyms |
Anti-Tac Humanized Monoclonal Antibody |
|
| Definitions |
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1569" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1569" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000042006 |
|
| altLabel |
Anti-Tac Humanized Monoclonal Antibody humanized anti-Tac monoclonal antibody monoclonal antibody anti-Tac Zenapax MOAB anti-Tac monoclonal antibody humanized anti-Tac Dacliximab anti-Tac monoclonal antibody anti-Tac |
|
| CAS Registry |
152923-56-3 |
|
| Component of | ||
| cui |
C0663182 C0281549 |
|
| Date last modified |
2006-08-01 |
|
| definition |
A recombinant monoclonal antibody interleukin-2 receptor antagonist. Daclizumab binds specifically to the alpha subunit of the human interleukin-2 (IL-2) receptor expressed on the surface of activated lymphocytes in vivo, thereby inhibiting IL-2 binding and IL-2-mediated lymphocyte activation, a critical cellular immune response pathway. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1569" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1569" NCI Thesaurus) |
|
| IND Code |
2091 |
|
| Legacy PDQ ID |
5231 |
|
| LT |
TRD |
|
| NCI ID |
C1569 |
|
| notation |
CDR0000042006 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
daclizumab |
|
| tui |
T116 T129 T121 |